MAY 02, 2018 08:00 AM PDT

Low Muscle Mass Could Be Affecting Breast Cancer Survival

In an article published in April 2018 in the journal JAMA Oncology, researchers from California evaluated the association of muscle and adipose tissue with survival rates of patients with nonmetastatic breast cancer.  They found that low muscle mass could be linked to poorer outcomes for patients.  The study included 3200+ women ages 18-80 diagnosed with stage II or III nonmetastatic breast cancer from the years 2000 to 2013. 

Sarcopenia, or low muscle mass, low muscle radiodensity, and total adipose tissue (TAT) were the factors of focus in their investigation.  The group utilized hazard ratios to account for associations of all-cause mortality with these three aforementioned factors.  Additionally, the analysis models were modified to account for sociodemographics, tumor specificities, treatment choices, body mass index (BMI), and additional body composition measures. The group wanted to evaluate these particular body composition measures for valuable options to assist in intervention guidance for better survival outcomes.

The measures of muscle mass, muscle radiodensity, and TAT were acquired through clinical computed tomography (CT) in this group of patients.  Low muscle radiodensity was not found to contribute to survival association, whereas low muscle mass and TAT provided significant prognostic information. 

Of the participants, 34% of nonmetastatic breast cancer patients presented with sarcopenia.  Those with sarcopenia showed higher overall mortality compared to those without.  Additionally, patients with high TAT showed higher overall mortality compared to those with low adiposity.  The group also created groupings of these factors and, not surprisingly, the highest mortality was observed in patients with both high TAT and low muscle mass.  The evidence did not, however, support the use of BMI as an overall mortality indicator and did not appropriately identify patients at risk of death based on body composition factors. 

As reported by the authors, sarcopenia is a largely unrecognized risk factor for overall mortality in this patient population.  This information, and adiposity at time of diagnosis, could contribute to a clinician’s approach for planning.  Of note, with the focus on body composition at the time of diagnosis, if changes in body composition took place to increase skeletal muscle mass and decrease TAT after diagnosis, could that positively shift the mortality risk?

Sources: JAMA Oncology, National Cancer Institute, Journal of Clinical Oncology, Journal of Cancer Survival, Nature Reviews Clinical Oncology,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 05, 2018
Cancer
JUN 05, 2018
Precision vs. Personalized Medicine Part II: Personalized Approach
So often the phrases "Precision Medicine" and "Personalized Medicine" are used interchangeably. Are they really synonyms? Part II looks at Personalized Medicine...
JUL 03, 2018
Cancer
JUL 03, 2018
Hereditary Myeloid Neoplasm Predisposition
New changes in myeloid classification help to outline a new category of AML which develops as a result of hereditary mutations predisposing family members to myeloid neoplasms in adulthood....
JUL 17, 2018
Cancer
JUL 17, 2018
Experimental "Trojan Horse" Tumor Destruction Approach Using CRISPR
CRISPR can be used to dupe circulating tumor cells into killing their own main tumor after "re-homing" back with a death receptor for tumor destruction....
AUG 02, 2018
Genetics & Genomics
AUG 02, 2018
The Genetic Hotspots That Can Lead to Cancer
In some of our body's tissues, cells have to replicate many times. That introduces a chance for new genetic errors every time....
SEP 15, 2018
Clinical & Molecular DX
SEP 15, 2018
Cancer & Anoikis: A Match Not Made in Heaven
Anoikis have always been intimately entwined with cancer, henceforth the quest to seek how they came to be as such....
OCT 04, 2018
Genetics & Genomics
OCT 04, 2018
Similar Processes Drive the Development of Lung and Prostate Cancers
Small cell cancers often have poor prognoses....
Loading Comments...